Using hair to manage HIV/AIDS and predict treatment successMarch 04, 2009UCSF researchers have found that examining levels of antiretroviral drugs in hair samples taken from HIV patients on therapy strongly predicts treatment success. The findings, published in the February 20 issue of AIDS, note that the levels of antiretrovirals found in the hair of patients on treatment correlated strongly with levels of HIV virus circulating in patients' blood. "High levels of antiretrovirals in hair correlated with success in HIV viral suppression in treatment and did so better than any of the other variables usually considered to predict response," said the study's primary investigator, Monica Gandhi, MD MPH, assistant professor of medicine at UCSF's Positive Health Program at San Francisco General Hospital. Typically, clinicians rely on either self-report by patients, pill counts or expensive medication dispensing devices to monitor how well patients are taking their pills as directed. These methods are highly patient dependent and have not been good predictors of treatment success. Clinicians can draw blood and then measure plasma levels of medications, but since a single plasma level represents medication exposure only hours prior to the blood draw, this method has also not been a good predictor of viral suppression, according to Gandhi. Single drug levels can vary day-by-day for a single patient and may reflect improved pill-taking by patients just before clinic visits, she said. Hair, which grows at a rate of about a centimeter a month, gives a reading of drug levels that reflects the rate of pill consumption sustained by patients over weeks, not days. Assessing an average level of drug exposure over time may be more predictive of treatment response than the "snapshot" of exposure provided by a single plasma level of medication, Gandhi said. "Hair sampling for antiretroviral levels could become a new standard to look at how much drug a patient is getting-an equivalent in HIV clinical care of measuring hemoglobin A1C, the method used in diabetes to monitor average blood glucose levels," said study co-investigator, Ruth M. Greenblatt, MD, UCSF professor of clinical pharmacy and principal investigator of the Women's Interagency HIV study. Researchers took 10 strands of hair from patients on HIV therapy from the back of the head. They cut the hair sample close to the scalp underneath the top layer of hair, marked the part farthest from the scalp with tape and wrapped the strands in aluminum foil. The sample was then stored at room temperature in a plastic bag until it was analyzed. "This is a painless, bloodless, biohazard-free, method of collecting a stable specimen from HIV patients that may allow for the monitoring of levels of antiretroviral drugs absorbed over time and the prediction of treatment success," said Gandhi. "Our next step is to test this method in resource-limited settings where blood collection and viral load monitoring may be expensive and difficult. Not only could this method help in measuring pill-taking, but its strong correlation with viral suppression could allow its use as an inexpensive, non-invasive method of monitoring treatment success in particularly challenging settings." Researchers from this group are also collaborating with public health researchers in testing hair to monitor pill-taking in clinical trials of single or dual antiretrovirals in high risk, HIV negative individuals to prevent infection with HIV (pre-exposure prophylaxis, known as PrEP, trials). The 224 patients in this study were drawn from the Women's Interagency HIV study, an ongoing multi-center, prospective study of HIV-infected and at risk uninfected women established in 1994. "Women taking antiretroviral medications may have more adverse events than men taking these regimens. The safety trials of these medications were conducted in trials consisting largely of men, and the highest tolerable amount of drug in order to successfully suppress HIV is usually recommended. One foreseeable use of this technique may be to fine-tune the amount of drug prescribed. We could measure drug levels in hair, find the level correlating with viral suppression, and then reduce the amount of drug prescribed if it was at a point exceeding the level needed for viral control, hopefully reducing toxicities," said Gandhi. University of California - San Francisco |
|||||||||||||||||||||
| Related Antiretroviral Drugs Current Events and Antiretroviral Drugs News Articles HIV integrase inhibitor effective for patients beginning antiretroviral treatment A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs. Protein excreted in urine may be help in diagnosing kidney disease caused by HIV New data collected at Columbia University Medical Center and by the Mount Sinai School of Medicine are helping researchers understand the extent to which a certain protein - NGAL - can play a significant role in marking chronic kidney disease resulting from HIV while at the same time distinguishing nephropathy from more common causes such as diabetes and hypertension. A new weapon in the war against HIV-AIDS: Combined antiviral and targeted chemotherapy A discovery by a team of Canadian and American researchers could provide new ways to fight HIV-AIDS. According to a new study published in Nature Medicine, HIV-AIDS could be treated through a combination of targeted chemotherapy and current Highly Active Retroviral (HAART) treatments. Researchers uncover approach for possibly eradicating HIV infection Researchers from the newly-established VGTI Florida and the University of Montreal have uncovered a possible method for eradicating HIV infection in the human body. AIDS patients with serious complications benefit from early retroviral use, Stanford study shows HIV-positive patients who don't seek medical attention until they have a serious AIDS-related condition can reduce their risk of death or other complications by half if they get antiretroviral treatment early on. Transmission of drug-resistant HIV-1 Drug-resistant forms of HIV can be spread between individuals who have not received anti-retroviral treatment. New Stanford list of HIV mutations vital to tracking AIDS epidemic In a collaborative study with the World Health Organization and seven other laboratories, researchers at the Stanford University School of Medicine have compiled a list of 93 common mutations of the AIDS virus associated with drug resistance that will be used to track future resistance trends throughout the world. IL-2 immunotherapy fails to benefit HIV-infected individuals already taking antiretrovirals Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone. Model of pre-exposure prophylaxis against HIV forecasts benefits, potential cost-effectiveness For every two people who begin treatment for HIV infection globally, five others become newly infected. Therefore, preventing new HIV infections is the foremost strategy for ending the HIV/AIDS epidemic. Landmark study defines benefits of early HIV testing and treatment for infected infants Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine. More Antiretroviral Drugs Current Events and Antiretroviral Drugs News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||